深圳市海王英特龙生物技术股份有限公司2025年年报

ANNUAL REPORT年 報2025 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGEOF HONG KONG LIMITED (THE “STOCK EXCHANGE”) GEM GEM has been positioned as a market designed to accommodatesmall and mid-sized companies to which a higher investment riskmay be attached than other companies listed on the Stock Exchange.Prospective investors should be aware of the potential risks ofinvesting in such companies and should make the decision to investonly after due and careful consideration. GEM Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may bemore susceptible to high market volatility than securities traded onthe Main Board and no assurance is given that there will be a liquidmarket in the securities traded on GEM. GEMGEMGEM Hong Kong Exchanges and Clearing Limited and the Stock Exchange take noresponsibility for the contents of this report, make no representation as to itsaccuracy or completeness and expressly disclaim any liability whatsoever forany loss howsoever arising from, or in reliance upon, the whole or any partof the contents of this report. G E MGEM This report, for which the Directors (the “Directors”) of Shenzhen NeptunusInterlong Bio-technique Company Limited (the “Company”) collectively andindividually accept full responsibility, includes particulars given in compliancewith the Rules Governing the Listing of Securities on GEM of the StockExchange (the “GEM Listing Rules”) for the purpose of giving informationwith regard to the Company. The Directors, having made all reasonableenquiries, confirm that to the best of their knowledge and belief theinformation contained in this report is accurate and complete in all materialrespects and not misleading or deceptive, and there are no other mattersthe omission of which would make any statement herein or this reportmisleading. Corporate Information公司資料 Directors Executive DirectorsMr. Zhang Feng(Chairman)Mr. Huang Jian BoMr. Zhang Xiao Guang Non-Executive DirectorsMr. Zhang Yi FeiMs. Yu LinMr. Jin Rui Independent Non-Executive Directors Mr. Yick Wing Fat, SimonMr. Poon Ka YeungMr. Zhang Jian Zhou Supervisors Mr. Xiong Chu XiongMr. Jin GeMs. Cao Yang Members of Remuneration Committee Mr. Poon Ka Yeung(Chairman of the Remuneration Committee)Mr. Zhang FengMr. Yick Wing Fat, Simon Members of Audit Committee Mr. Yick Wing Fat, Simon(Chairman of the Audit Committee)Mr. Poon Ka YeungMs. Yu Lin Members of Nomination Committee Mr. Zhang Feng(Chairman of the Nomination Committee)Ms. Yu LinMr. Yick Wing Fat, SimonMr. Poon Ka YeungMr. Zhang Jian Zhou Company Secretaries Mr. Huang Jian BoMs. Fung Wai Sum Compliance OfficerMr. Zhang Feng Authorised Representatives Mr. Zhang FengMr. Huang Jian Bo AuditorsGrant Thornton Hong Kong Limited 97943 Legal Adviser Stephenson Harwood43/F, One Taikoo Place, 979 King’s Road, Quarry Bay, Hong Kong Principal Bank China Construction Bank Shenzhen CBD Sub-branch H1617 H Share Registrar and Transfer Office Tricor Investor Services Limited17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong Registered Office 11702 Suite 1702, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road,Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, ThePRC 97943 Principal Place of Business in Hong Kong 43/F, One Taikoo Place, 979 King’s Road, Quarry Bay, Hong Kong www.interlong.com Websitewww.interlong.com 8329 Stock Code8329 Chairman’s Statement主席報告 Dear Shareholders, On behalf of the Board of Directors (the “Board”) of the Company, I ampleased to present the annual results of the Company and its subsidiaries(collectively the “Group”) for the year ended 31 December 2025 (the“Year”). In 2025, China’s pharmaceutical industry was characterized by a coexistenceof market consolidation and restructuring alongside a surge in innovation,with the overall downsizing of the end-user pharmaceutical market. In termsof market segments, the market shares of retail pharmacies and hospitalsgradually decreased, while online channels saw notable growth. In termsof major product categories, innovative chemical and biopharmaceuticalsmaintained a sustained growth trend, while traditional categories such asgeneric drugs, traditional Chinese medicine and medical devices experiencedsluggish growth or slight declines. Against the backdrop of normalizedvolume-based procurement and refined medical insurance cost control, thebusiness model of promoting traditional products through conventionalmarketing channels is facing an increasingly competitive market environment. OTC In 2025, the Group recorded a loss for the first time in over a decade. Thiswas primarily due to the underperformance of Beijing Neptunus ZhongxinPharmaceutical Co., Ltd.* (, “NeptunusZhongxin”), which the Group acquired in mid-2021. Consequently, thegoodwill arising from the acquisition underwent a routine impairment testduring the current year, resulting in a full impair